FIELD: medicine, pharmaceutics.
SUBSTANCE: there are presented: a product for treating pulmonary arterial hypertension containing macitentan or its pharmaceutically acceptable salt in a combination with a prostacyclin receptor (IP) agonist specified in iloprost, beraprost, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulphonyl)acetamide, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid or their pharmaceutically acceptable salt (versions), a pharmaceutical composition for the same application and formulation of the active agents. What is also presented is using macitentan or its salt in a combination with the above agonist for preparing the therapeutic agent for treating pulmonary arterial hypertension.
EFFECT: what is shown is synergic action (double effect) of the declared combinations 
10 cl, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CRYSTALS | 2010 |
|
RU2556206C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING 2-{4-[N-(5,6-DIPHENYLPYRAZIN-2-YL)-N-ISOPROPYLAMINO]BUTYLOXY}-N-(METHYLSULPHONYL)ACETAMIDE | 2016 |
|
RU2735547C2 |
| HETEROCYCLIC COMPOUND DERIVATIVES AND PHARMACEUTICAL AGENTS | 2002 |
|
RU2283835C2 |
| DERIVATIVES OF 4-(THIO- OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND USING | 2002 |
|
RU2314305C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING NEP-INHIBITORS, INHIBITORS OF ENDOGENOUS ENDOTHELIN-PRODUCING SYSTEM AND AT-RECEPTOR ANTAGONISTS | 2005 |
|
RU2384346C2 |
| DERIVATIVES OF CARBAMIC ACID, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHOD OF HEALING | 1999 |
|
RU2179969C2 |
| NEW EP4 AGONIST | 2011 |
|
RU2564414C2 |
| FIBROSIS INHIBITOR | 2009 |
|
RU2497525C2 |
| COMBINATION THERAPY OF PULMONARY HYPERTENSION | 2016 |
|
RU2780758C2 |
| THERAPEUTIC AGENT FOR TREATING HYPERTENSION | 2006 |
|
RU2415147C2 |
